MANGOCEUTICALS, INC. 8-K

What Happened
Mangoceuticals, Inc. (MGRX) filed a Form 8-K on February 23, 2026 (Regulation FD disclosure) and issued a press release announcing new data for its proprietary, patented antiviral compound MGX-0024. The company reported zero respiratory-related mortality in approximately 29,000-bird commercial poultry field trials conducted in India and described prophylactic benefits against H5N1 in a government-conducted challenge study.

Key Details

• Date filed/announced: February 23, 2026 (press release furnished as Exhibit 99.1 to the 8-K).
• Field trials: ~29,000 commercial poultry in India with reported zero respiratory-related mortality.
• Controlled study: Government-conducted challenge study showed prophylactic (preventive) benefits against H5N1.
• Product: MGX-0024 is described as the company’s proprietary, patented antiviral compound.

Why It Matters
These results, if confirmed and validated, are material because they indicate potential safety and efficacy signals for MGX-0024 in large commercial poultry settings and in a government challenge model for H5N1—data types that can affect regulatory discussions, commercialization prospects, and investor sentiment. The filing is a Regulation FD disclosure of a press release; it does not replace detailed study reports or regulatory filings. Investors should review the full press release and subsequent company disclosures for complete data, study design details, and any regulatory or commercial plans. The company also included standard forward-looking statement caution about risks and uncertainties.